Actively Recruiting

Phase Not Applicable
Age: 18Years +
All Genders
ID06069297

Multimodal Prehabilitation in Localized Pancreatic Cancer Patients Undergoing Surgery: a Randomized Controlled Trial

Led by IRCCS San Raffaele · Updated on 2025-08-01

238

Participants Needed

1

Research Sites

52 weeks

Total Duration

On this page

Sponsors

I

IRCCS San Raffaele

Lead Sponsor

M

Ministero della Salute, Italy

Collaborating Sponsor

AI-Summary

What this Trial Is About

Researchers are evaluating the effects of a four-week multimodal prehabilitation program on patients with localized pancreatic or periampullary cancer who are scheduled for curative surgery. This trial aims to improve postoperative outcomes by addressing common risk factors such as older age, frailty, multiple health conditions, and malnutrition. The study also explores how prehabilitation influences biomarkers linked to muscle wasting and cancer cachexia in pancreatic ductal adenocarcinoma (PDAC) patients. Participants will be randomly assigned to either the intervention group, receiving a supervised multimodal prehabilitation program including physical exercise, nutritional support, and psychosocial counseling for at least four weeks before surgery, or to a control group receiving usual care with educational materials about healthy lifestyle and surgery preparation. Both groups will undergo the same surgical and postoperative care based on enhanced recovery protocols. During the study, patients will undergo baseline assessments of medical history, physical performance, nutritional status, body composition, autonomic nervous system activity, and quality of life through various tests and questionnaires. These evaluations will be repeated before surgery and at 30, 60, and 90 days after surgery to monitor recovery, functional capacity, nutritional status, body composition, psychological well-being, and complications. Blood samples will be collected to analyze inflammatory and cachexia-related factors. The study includes follow-up visits and phone contacts to track patient progress over time.

CONDITIONS

Brief Title

Prehabilitation in Pancreatic Surgery

Who Can Participate

Age: 18Years +
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Age 18 years or older
  • Scheduled for curative surgery for pancreatic or periampullary cancer
  • Signed informed consent
Not Eligible

You will not qualify if you...

  • Metastatic or unresectable disease found before surgery
  • Comorbidities preventing exercise or nutritional interventions such as orthopedic or cognitive disabilities or severe kidney failure
  • ASA score of 4 or 5
  • Pregnancy
  • Inability to read and understand Italian language (illiteracy)

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Your Study Journey

Screening

Duration - 2 to 4 weeks

Participants are screened for eligibility to participate in the trial.

1 visit (in-person)

Preoperative Assessment and Baseline Measurements

Duration - 1 day

Participants undergo comprehensive baseline evaluations including medical history, physical performance tests, nutritional assessments, body composition measurements, autonomic nervous system activity, patient-reported outcome questionnaires, and blood sample analysis.

1 visit (in-person)

Multimodal Prehabilitation or Usual Care

Duration - 4 to 6 weeks

Participants are randomized to receive either a 4 to 6-week multimodal prehabilitation program including exercise training, nutritional therapy, and psychosocial counseling, or usual preoperative care with informative material. This aims to improve functional capacity and prepare participants for surgery.

Exercise sessions 2 to 3 times per week plus nutritional and psychological counseling visits during this period

Pre-surgery Re-evaluation

Duration - 1 day

One day before surgery, participants repeat the baseline assessments to evaluate functional capacity, nutritional status, body composition, quality of life, and related measures.

1 visit (in-person)

Surgery and Hospital Stay

Duration - Variable depending on hospital stay

Participants undergo pancreatic surgery followed by hospital stay where postoperative outcomes and complications are monitored and recorded.

Routine hospital visits during inpatient stay

Postoperative Follow-up and Recovery

Duration - 90 days

Participants are followed up at 30, 60, and 90 days after surgery during scheduled outpatient visits to assess recovery, including functional capacity, nutritional status, body composition, quality of life, anxiety and depression, and patient engagement.

3 outpatient visits at 30, 60, and 90 days post-surgery plus phone calls from nurse navigator

Trial Site Locations

Total: 1 location

1

San Raffaele Hospital

Milan, Lombardy, Italy, 20132

Actively Recruiting

Loading map...

Research Team

N

Nicolò Pecorelli, MD

F

Francesca Di Salvo, PhD

How is the study designed?

Study Type

INTERVENTIONAL

Masking

SINGLE

Allocation

RANDOMIZED

Model

PARALLEL

Primary Purpose

PREVENTION

Number of Arms

2

Similar Trials

Evaluation of Diagnostic Value of 18F-T2 PET/ CT Imaging for...

Clear Cell Renal Cell Cancer (ccRCC)

Actively Recruiting

1 location

A Phase 1/2a Study Utilizing 64Cu-LNTH-1363S (64Cu Radiolabe...

Metastatic Sarcoma

Actively Recruiting

5 locations

Frequently Asked Questions

Have more questions? Get in touch with our team for quick support

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here

Published Research Related To This Trial

The Impact of Prehabilitation on Patient Outcomes in Hepatobiliary, Colorectal, and Upper Gastrointestinal Cancer Surgery: A PRISMA-Accordant Meta-analysis.

Joel E Lambert, Lawrence D Hayes, Thomas J Keegan...

https://pubmed.ncbi.nlm.nih.gov/33201129

Multimodal Prehabilitation In Pancreatic cancer Patients undergoing surgery (PIPS): study protocol for a randomized controlled trial.

Nicolò Pecorelli, Francesca Fermi, Martina Abati...

https://pubmed.ncbi.nlm.nih.gov/41618415